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Objective: Insulin resistance is a common feature of polycystic ovary syndrome (PCOS). The insulin
signaling pathway consists of two major pathways, the metabolic and the mitogenic cascades. The many
components of these pathways have not been comprehensively analyzed for differential expression in
insulin-responsive tissues in PCOS. The goal of this study was to determine whether the core elements of
the insulin signal transduction cascade were differentially expressed in subcutaneous adipose tissue
(SAT) between PCOS and controls.
Materials/methods: Quantitative real-time PCR for 36 insulin signaling pathway genes was performed in
subcutaneous adipose tissue from 22 white PCOS and 13 healthy controls.
Results: Genes in the insulin signaling pathway were not differentially expressed in subcutaneous adi-
pose tissue between PCOS and controls (P > 0.05 for all). Components mainly of the mitogenic pathway
were correlated with both androgens and metabolic phenotypes. Expression levels of ﬁve genes (MKNK1,
HRAS, NRAS, KRAS, and GSK3A) were positively correlated with total testosterone level (r > 0, P < 0.05).
Inverse correlation was found between expression of six genes (HRAS, MAP2K2, NRAS, MAPK3, GRB2, and
SHC1) and metabolic traits (body mass index, fasting glucose, fasting insulin, and HOMA-IR) (r < 0,
P < 0.05).
Conclusions: Differential expression of core insulin signaling pathway components in subcutaneous
adipose tissue is not a major contributor to the pathogenesis of PCOS. Correlation between clinical
phenotypes and expression of several genes in the mitogenic limb of the insulin signaling pathway
suggests mitogenic signaling by insulin may regulate steroidogenesis and glucose homeostasis.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).ubcutaneous adipose tissue,
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Polycystic ovary syndrome (PCOS), characterized by hyper-
androgenism, polycystic ovaries and oligo-ovulation, affects 7e10%
of reproductive age women [1]. Women with PCOS disproportion-
ately manifest insulin resistance, obesity, diabetes mellitus and
cardiovascular disease. Approximately 50%e70% of all PCOSwomen
demonstrate some degree of insulin resistance, as determined by a
variety of methods [1]. As a consequence of insulin resistance, PCOS
patients often present with compensatory hyperinsulinemia, which
exacerbates hyperandrogenemia by promoting ovarian androgennder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Clinical characteristics of PCOS and control subjects
Control (n ¼ 13) PCOS (n ¼ 22) P value
Age (yr) 33.0 (13.0) 28.0 (3.3) 0.042
BMI (kg/m2) 25.5 (8.7) 31.0 (8.0) 0.23
Insulin (pmol/l) 57.0 (48.0) 54.0 (69.0) 0.46
Glucose (mmol/l) 4.14 (1.28) 4.97 (0.55) 0.030
HOMA-IR 1.09 (0.46) 1.01 (1.08) 0.99
HOMA-%B 122.4 (75.3) 89.0 (44.6) 0.17
Total testosterone (nmol/l) 0.97 (0.29) 1.11 (0.99) 0.079
Free T (nmol/l) 0.080 (0.074) 0.18 (0.14) 0.0013
DHEAS (mmol/l) 5.41 (4.32) 6.60 (3.68) 0.038
mFG 0 (1) 7 (5) <0.0001
BMI, body mass index; DHEAS, dehydroepiandrosterone sulfate; HOMA-IR, ho-
meostasis model assessment of insulin resistance; HOMA-%B, homeostasis model
assessment of beta-cell function (insulin secretion); mFG, modiﬁed Ferriman-
Gallwey score to evaluate hirsutism in women.
Data are median (interquartile range). P values are derived from theManneWhitney
test.
N. Xu et al. / Journal of Clinical & Translational Endocrinology 2 (2015) 99e104100production and suppressing sex-hormone binding globulin levels
[1,2]. That many features of PCOS improve on treatment with in-
sulin sensitizing medications suggests that insulin resistance may
be integral to the pathogenesis of PCOS [3].
Given that both PCOS and insulin resistance are heritable [4], the
insulin signaling pathway provides a number of candidate genes
that might illuminate the pathogenesis of PCOS. Only a handful of
the many possible genes coding for components of the insulin
signaling pathway were initially investigated in single nucleotide
polymorphism (SNP) association studies [5]. We extensively inter-
rogated the entire regions of w30 genes comprising the core
components of the classic metabolic limb of the insulin signaling
pathway as well as the novel CAP/Cbl pathway, identifying several
SNPs associated with PCOS in a discovery cohort; association with
PCOS of one SNP, rs2252673, in the insulin receptor (INSR) genewas
conﬁrmed in a replication cohort [6]. Until the latter study, the
majority of association studies of INSR in PCOS had focused only on
a single variant [7]. Several studies describing association with
PCOS of the D19S884 microsatellite provide further support of a
potential role of INSR in the inheritance of PCOS [8,9]. Most
convincingly, a recent genome-wide association study identiﬁed
eight new risk loci for PCOS, including rs2059807, a SNP within an
intron of the INSR gene [10]. This conﬁrms the signiﬁcance of INSR,
and suggests a possible effect on the downstream insulin signaling
events that follow binding of insulin in PCOS pathogenesis.
The insulin signaling cascade is initiated when insulin binds to
the a-subunit of the insulin receptor, activating the tyrosine kinase
activity in the b-subunit, which results in phosphorylation of the
intermediates phosphatidylinositol-3-kinase (PI3K) and MAP ki-
nase (MAPK) (Fig. 1). Activation of PI3K leads to a cascade of
downstream signals (termed the PI3K pathway or metabolic
pathway) that promote metabolic effects such as glucose uptakeFig. 1. Core components of the insulin signaling pathway. The metabolic (PI3K) and mitogen
genes whose expression was analyzed are indicated. Names containing a slash indicate isofo
PIP3 ¼ phosphatidylinositol (3,4,5)-trisphosphate. Full gene names are listed in Supplemenand glycogen synthesis. The activation of the MAPK cascade pro-
motes gene expression and cell growth, comprising the mitogenic
pathway [11] (Fig. 1).
Women with PCOS often have abdominal obesity, and gene
expression proﬁling experiments suggest dysfunction of visceral fat
plays an important role in PCOS [12]. However, visceral fat is not the
only determinant of insulin resistance, and a substantial proportion
of lean PCOS women are insulin resistant as well [13]. In addition to
visceral adipose tissue, dysfunction of subcutaneous adipose tissue
(SAT) also contributes to insulin resistance and obesity; SAT mass
and capacity for fat storage inﬂuence insulin sensitivity, indepen-
dent of visceral fat [14,15]. Investigators have successfully utilized
SAT to demonstrate adipose tissue dysfunction in PCOS. Aic (MAPK) limbs of the insulin signaling pathway were studied. The products of the 36
rms encoded by different genes. Flat arrows indicate inhibition. p ¼ phosphate group;
tal Table 1.
Table 2
Relative gene expression levels and fold change for core factors in the insulin
signaling pathway of PCOS and control subjects
Gene name Controls (DCt) PCOS (DCt) DDCt Fold change P value
AKT1 0.557 (1.367) 0.487 (0.935) 0.042 1.03 0.99
AKT2 0.371 (1.681) 0.708 (1.24) 0.011 1.01 0.93
AKT3 1.998 (0.544) 2.171 (0.96) 0.199 0.87 0.25
ELK1 2.851 (0.795) 2.675 (0.734) 0.184 0.88 0.93
GRB2 0.856 (0.619) 0.869 (0.405) 0.148 1.11 0.33
GSK3A 0.0135 (0.628) 0.0149 (0.987) 0.174 0.89 0.80
GSK3B 1.256 (0.518) 1.312 (0.369) 0.035 0.98 0.57
GYS1 1.745 (0.831) 1.231 (1.168) 0.233 1.18 0.27
GYS2 5.356 (1.638) 5.456 (1.965) 0.089 0.94 0.67
HRAS 1.600 (1.134) 1.202 (1.009) 0.123 1.09 0.24
INSR 1.171 (0.719) 1.425 (0.649) 0.245 0.84 0.094
IRS1 1.630 (0.876) 1.817 (1.129) 0.309 0.81 0.44
IRS2 0.301 (1.233) 0.406 (0.771) 0.159 0.90 0.37
KRAS 4.136 (0.661) 4.111 (0.583) 0.028 1.02 0.77
MAP2K1 1.416 (0.62) 1.416 (0.301) 0.006 1.00 0.80
MAP2K2 1.778 (0.592) 1.453 (0.58) 0.183 1.14 0.20
MAPK1 0.673 (0.617) 0.876 (0.482) 0.160 0.90 0.13
MAPK3 0.353 (0.709) 0.307 (0.539) 0.055 0.96 0.67
MKNK1 1.655 (0.713) 1.926 (0.895) 0.223 0.86 0.69
MKNK2 0.563 (0.736) 0.637 (0.923) 0.277 0.83 0.30
NRAS 1.101 (0.552) 0.893 (1.059) 0.039 0.97 0.53
PDPK1 1.224 (0.752) 1.371 (0.985) 0.213 0.86 0.77
PIK3CA 1.566 (0.861) 1.912 (0.623) 0.267 0.83 0.14
PIK3CB 2.095 (0.653) 2.222 (0.645) 0.136 0.91 0.30
PIK3R1 1.646 (1.288) 1.456 (0.916) 0.006 1.00 0.93
PIK3R2 2.245 (0.372) 1.962 (0.533) 0.188 1.14 0.14
PRKCI 7.222 (0.76) 7.392 (0.816) 0.387 0.77 0.37
PRKCZ 6.173 (1.082) 6.962 (1.236) 0.655 0.64 0.082
PTEN 0.519 (0.852) 0.55 (0.579) 0.209 0.87 0.75
PTPN1 1.799 (1.059) 1.879 (0.833) 0.052 0.96 0.85
RAF1 3.533 (0.624) 3.383 (0.485) 0.072 0.95 0.96
SHC1 0.183 (1.085) 0.676 (0.98) 0.041 1.03 0.28
SHC2 2.513 (0.766) 2.858 (0.816) 0.023 0.98 0.88
SLC2A4 0.803 (1.715) 0.0649 (1.686) 0.065 1.05 0.75
SOS1 0.589 (0.612) 0.544 (0.62) 0.222 1.17 0.21
SOS2 1.630 (0.43) 1.714 (0.641) 0.065 0.96 0.77
DCt data aremedian (interquartile range).P valueswerederived fromManneWhitney
tests comparing DCt values between women with PCOS and controls.
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SAT from non-obese PCOS, revealing differentially expressed genes
involved in inﬂammation, lipid metabolism andWnt signaling [16].
SAT from non-obese PCOS women had increased expression of the
genes for CD11c (a proinﬂammatory macrophage marker), leptin,
and tumor necrosis factor alpha and decreased expression of
peroxisome proliferator-activated receptor gamma [17,18].
Compared to body mass index (BMI)-matched controls, PCOS
women had increased SAT on magnetic resonance imaging, which
correlated negatively with insulin sensitivity [17]. The above ﬁnd-
ings highlight the importance of SAT in PCOS and insulin resistance.
To test the hypothesis that the insulin signaling pathwaymay be
disrupted in PCOS, we analyzed the core elements of the insulin
signal transduction cascade in SAT of PCOS women and controls,
looking for differential gene expression.
Materials and methods
Subjects
For mRNA analysis, subcutaneous lower abdominal adipose
tissue was obtained from 22 white PCOS and 13 white control
subjects (clinical characteristics are shown in Table 1); we have
previously conducted expression studies in some [19] or all [20] of
these subjects. The protocol for acquiring and processing SAT was
previously described [21]. Cases were premenopausal, non-
pregnant, on no hormonal therapy, including oral contraceptives,
for at least 3 months, and met the National Institutes of Health
(NIH) 1990 criteria for the diagnosis of PCOS. Parameters for
deﬁning hirsutism, hyperandrogenemia, ovulatory dysfunction,
and exclusion of related disorders have been reported previously
[22]. Controls were healthy women with regular menstrual cycles,
no evidence of hirsutism, acne, alopecia, or endocrine dysfunction,
and had not taken hormonal therapy (including oral contracep-
tives) for at least 3 months. Controls were recruited by word of
mouth and advertisements calling for healthy women.
Fasting blood was obtained in cycle days 3e8 (follicular phase)
after a spontaneous menstrual cycle or a progesterone-induced
withdrawal bleed. Homeostasis model assessment of insulin
resistance (HOMA-IR) and beta cell function (HOMA-%B) were
calculated using the web tool at http://www.dtu.ox.ac.uk/
homacalculator/index.php.
Ethical approval
All subjects gave informed written consent, according to the
guidelines of the institutional review board at Cedars-Sinai Medical
Center.
Quantitative real-time PCR (qRT-PCR) gene expression analysis
Total RNAwas isolated from SATafter rapid thawwith the AllPrep
DNA/RNA/protein minikit (QIAGEN, Valencia, CA, U.S.A.) and was
quantiﬁed and checked for quality (260/280 and 260/230 ratios) on a
Nanodrop-1000 (Nanodrop, Wilmington, DE, U.S.A.). The integrity of
RNAwas checked by Bioanalyzer (RIN ¼ 7.6e9.8). cDNA was created
using the Applied Biosystems High-Capacity cDNA Reverse Tran-
scription Kit (Life Technologies, Carlsbad, CA, U.S.A.). According to the
manufacturer’s protocol, 10 ml of RNA at 5 ng/ml was used to generate
cDNA. A pre-ampliﬁcation protocol was then performed using the
Taqman PreAmpMasterMix (Life Technologies) and a custompool of
primers for 38 gene expression targets following the manufacturer’s
directions. The genes consisted of two housekeeping genes (GAPDH,
GUSB), plus genes for 36 insulin signaling elements (AKT1, AKT2,
AKT3, ELK1, GRB2, GSK3A, GSK3B, GYS1, GYS2, HRAS, IRS1, IRS2, INSR,KRAS, MAP2K1, MAP2K2, MAPK1, MAPK3, MKNK1, MKNK2, NRAS,
PDPK1, PI3KCA, PI3KCB, PI3KR1, PI3KR2, PRKCI, PRKCZ, PTEN, PTPN1,
RAF1, SHC1, SHC2, SLC2A4, SOS1, SOS2) (gene names and assay
numbers are listed in Supplemental Table 1); these 36 genes were
selected because they are integral to the metabolic and mitogenic
limbs of the insulin signaling pathway (Fig. 1). Quantitative RT-PCR
analysis was performed using the OpenArray platform and Taqman
gene expression assays (Life Technologies). Samples were run in
technical triplicate with a no template control carried forward from
cDNA generation. The housekeeping genes GAPDH and GUSB were
used for signal normalization. The results were analyzed using the
DDCt relative quantiﬁcation method [23]. Relative mRNA expression
levels of each transcript in PCOS tissues were compared by fold
change to the control samples; average cycle threshold (Ct) values of
each group were adjusted by subtracting the average Ct values of the
housekeeping genes, yielding DCt. The DDCt for each transcript
across groupswas calculated asDDCt¼ DCtPCOS DCtcontrols. The fold
change of PCOS relative to controls was calculated as 2(DDCt).
Statistical analysis
ManneWhitney tests were used to compare clinical character-
istics between cases and controls. Data are presented as median
(interquartile range). The DCt for PCOS versus controls from qRT-
PCR was subjected to ManneWhitney tests. Logistic regression
was used to adjust for age and BMI, to avoid their potential effects
on expression of genes coding for components of the insulin
Table 3
Correlation between clinical traits and gene expression levels (DCt)
Traits Gene symbol Spearman r P value
Androgens
Total testosterone MKNK1 0.43 0.025
Total testosterone HRAS 0.43 0.027
Total testosterone NRAS 0.42 0.030
Total testosterone KRAS 0.39 0.042
Total testosterone GSK3A 0.39 0.046
DHEAS RAF1 0.40 0.044
Metabolic traits
BMI GRB2 0.42 0.013
BMI HRAS 0.44 0.0078
BMI MAP2K2 0.37 0.031
BMI NRAS 0.39 0.022
Glucose MAPK3 0.50 0.013
Glucose NRAS 0.42 0.043
HOMA-IR GRB2 0.56 0.017
HOMA-IR MAPK3 0.64 0.0043
Insulin GRB2 0.43 0.048
Insulin HRAS 0.46 0.030
Insulin MAPK3 0.58 0.0050
Insulin NRAS 0.52 0.014
Insulin SHC1 0.53 0.012
P values were derived from Spearman’s rank correlation.
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between gene expression levels (DCt) and quantitative traits in the
entire cohort. All statistical tests were performed in JMP 9.0 (SAS
Institute Inc., Cary, NC, U.S.A.), and signiﬁcance was taken as
P < 0.05.
Results
PCOS women and controls were similar in BMI; however, PCOS
women were slightly but statistically signiﬁcantly younger than
controls (Table 1). Expression levels of all core factors in the insulin
signaling pathway were examined by qRT-PCR. Table 2 displays the
median (inter-quartile range) of theDCt for each transcript, aswell as
fold change. No genes were differentially expressed between PCOS
andcontrols. Adjustment forageandBMIdidnotmodify theseresults.
We conducted exploratory analyses wherein we evaluated cor-
relations between gene expression levels and quantitative pheno-
types. The exact correlation coefﬁcient r values are shown in
Table 3. For androgens, positive correlation was found between
expression of ﬁve genes (MKNK1,HRAS,NRAS, KRAS, and GSK3A) and
total testosterone level (r > 0, P < 0.05). In contrast, metabolic
traits, including BMI, fasting insulin, HOMA-IR, and fasting glucose,
were inversely correlated with expression of several genes (HRAS,
MAP2K2, NRAS, MAPK3, GRB2, and SHC1) (r < 0, P < 0.05). No gene
expressionwas correlatedwith HOMA-%B. All genes (except GSK3A)
whose transcripts were correlated with clinical traits belong to the
mitogenic limb of the insulin signaling pathway (Fig. 1). Of note,
these exploratory correlation analyses were conducted in the entire
cohort to maximize sample size. We also performed correlation
analyses stratiﬁed by PCOS diagnosis; several of the inverse corre-
lations seen in the entire group betweenmitogenic gene expression
and metabolic traits were also observed in the PCOS group. This
pattern was not clear in the control group, possibly due to reduced
sample size (Supplemental Table 2). Thus, we cannot deﬁnitively
comment on whether the observed correlation results are speciﬁc
to PCOS or to women in general.
Discussion
In women with and without PCOS, we analyzed the gene
expression of 36 elements of the insulin signal transductioncascade, from the insulin receptor through the distal effectors
downstream, which result in metabolic (PI3K pathway) and mito-
genic (MAPK pathway) effects (Fig. 1). We observed no differences
in expression in any of the insulin signaling pathway elements,
although there was a trend towards signiﬁcance for INSR
(P ¼ 0.094), with PCOS women demonstrating decreased INSR
expression versus controls. Interestingly, among insulin signaling
pathway genes, polymorphisms at the INSR locus have the best
evidence of associationwith PCOS [6,8e10]. Exploratory correlation
analysis between gene expression in SAT and clinical traits found
that several components of the mitogenic pathway were correlated
with both androgens and metabolic phenotypes.
Consistent with our results, prior microarray studies in adipose
tissuehavenot revealeddifferentialmRNAexpression of core insulin
signaling pathway components in women with PCOS compared to
controls [12,16]. Very few studies have examined mRNA levels of
speciﬁc insulin signaling pathway components; one found no dif-
ference in expression of the gene for the p85 subunit of PI3K [24] and
another found decreased expression of GLUT4 mRNA [19]. The
scarcity of such studies highlighted the need for the current study,
which examined mRNA levels for genes for all of the central ele-
ments in the metabolic and mitogenic insulin signaling pathways.
Differential mRNA expression of core signaling elements rep-
resents only one potential mechanism of pathway dysfunction.
Aberrant post-transcriptional or post-translational regulation may
exist in PCOS adipose, resulting in alterations in concentration and/
or phosphorylation of pathway proteins. Several studies have
examined protein levels of speciﬁc insulin signaling components in
adipose tissue from women with and without PCOS. Most of these
did not observe differences in protein levels (Akt-1, Akt-2, c-Cbl
associated protein (CAP), Cbl proto-oncogene, GLUT-4, insulin re-
ceptor b subunit, IRS-1, IRS-2, PKC-z, p85 subunit of PI3K) [24e26],
while others found decreased GLUT-4 protein [19,27] and decreased
protein levels and phosphorylation of IRS-1 [28]. Post-translational
regulation may alter activity of insulin signaling components even
in the absence of altered mRNA or protein levels, as has been seen
for PI3K and GSK-3b in PCOS adipose [21,24]. The current study,
focused on transcript levels, cannot evaluate these possibilities.
Interestingly, exploratory analyses found that expression levels
of several genes from the mitogenic limb of the pathway (and
GSK3A, which has effects on the cell cycle as well as metabolism
[29]) were correlated with androgen levels. In general, MAPK
signaling plays a role in processes such as cell differentiation, cell
proliferation, and cell death [30]. Members of the MAPK family
regulate steroid biosynthesis through effects on expression of ste-
roidogenic acute regulatory protein (StAR) [31]. Testosterone in
turn can activate MAPK signaling via the androgen receptor [32].
The cause-and-effect relationship underlying the positive correla-
tion between testosterone levels and expression of MAPK compo-
nents requires further investigation. This correlation raises the
possibility of interaction between MAPK signaling and testosterone
synthesis. These exploratory correlation analyses should be
considered hypothesis-generating as statistical signiﬁcancewas not
corrected for multiple testing.
Alternatively, we found inverse correlation between several
MAPK signaling pathway components and metabolic traits. This is
not in agreement with ﬁndings in PCOS skeletal muscle, in which
activation of the MAPK pathway may cause insulin resistance via
serine phosphorylation [33]. SAT may respond differently than
skeletal muscle to MAPK signaling. Members of the MAPK family
have effects on each step of adipocyte differentiation [34]. MAPKs
may play a role in “adipose tissue expandability,” which hypothe-
sizes that SAT has a limited capacity to expand [34,35]. Before the
maximal point of SAT expansion is reached, SAT storage capacity
prevents fat deposition in visceral adipose tissue, liver, and muscle,
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cations [35]. We hypothesize that increased expression of genes in
the mitogenic pathway contributes to increased amounts of SAT
available to store excess body fat.
Our study has several strengths. Our sample size was larger
than many prior expression studies in this ﬁeld. Our cases and
controls overlapped substantially in BMI (Table 1), precluding
concerns that any observed expression differences might be due
solely to differences in adiposity. Moreover, we investigated the
expression of the full complement of insulin signal transduction
elements, from proximal insulin receptor to distal metabolic and
mitogenic elements within an insulin target tissue. However,
although abdominal subcutaneous adipose signiﬁcantly modu-
lates total body insulin action [14,15], it is possible that alterations
in insulin signaling gene expression may exist in visceral adipose
tissue only or in other insulin target tissues, such as skeletal
muscle and liver. Another limitation of our study is that, although
larger than several prior studies, the number of samples studied is
still relatively small. Therefore, correlation analyses stratiﬁed by
PCOS diagnosis may generate unreliable results. In addition, one
possible reason for the lack of expression differences is that our
cases and controls were generally similar with respect to their
insulin dynamics; only fasting glucose approached signiﬁcance,
whereas differences in fasting insulin, HOMA-IR and HOMA-%B
were insigniﬁcant. Perhaps expression differences would have
been detectable if our cases and controls had been more divergent
in insulin sensitivity.
In conclusion, we contrasted the expression of genes involved in
the insulin signaling pathways in SAT derived from women with
PCOS and healthy controls. We did not ﬁnd expression differences
for any of the 36 components studied. This suggests that differential
mRNA expression of core insulin signaling pathway components in
this tissue is not a major contributor to the pathogenesis of PCOS.
Further studies will be needed to determinewhether this is the case
for other insulin responsive tissues.
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